CSNK2A1
ENSG00000101266
Target class
Kinase
Chromosome
20
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- Yes
- Target name
- CSNK2A1
- Gene name
- Casein kinase 2 alpha 1
- Gene symbol
- CSNK2A1
- Protein name
- Casein kinase II subunit alpha (CK II alpha) (EC 2.7.11.1)
- Cka1
- Cka2
- Gene biotype
- Protein coding
- Gene family
- Casein kinase 2 alpha family
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 73.2
- Tissue specificity (Gini)
- 0.207
- Tissue specificity (tau)
- 0.603
- KEGG gene identifiers
- hsa:1457
- Protein interaction confidence
- 0.831466
- Protein interaction partners
- 73
- R-HSA-1483191
- R-HSA-201688
- R-HSA-2514853
- R-HSA-445144
- R-HSA-6804756
- R-HSA-6814122
- R-HSA-8934903
- R-HSA-8939243
- R-HSA-8948751
- R-HSA-9755511
- R-HSA-9768727
- R-HSA-9828806
- R-HSA-9929491
- R-HSA-9931529
- R-HSA-9931530
- End position
- 543835
- Start position
- 472498
- Chromosome
- 20
- Strand
- Reverse
- Nucleus .
- Nucleoplasm
- PubMed 23123191
- PubMed 24962073
- Tissue specificity (tau)
- 0.602779
- Expression inequality (Gini)
- 0.206919
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 73.2
- Cells - Cultured fibroblasts
- 60.96
- Testis
- 43.56
- Uterus
- 41.89
- Skin - Sun Exposed (Lower leg)
- 41.61
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes73.2
- Cells - Cultured fibroblasts60.96
- Testis43.56
- Uterus41.89
- Skin - Sun Exposed (Lower leg)41.61
- Ovary41.53
- Cervix - Endocervix40.14
- Skin - Not Sun Exposed (Suprapubic)39.91
- Brain - Cerebellar Hemisphere39.66
- Cervix - Ectocervix39.25
- Bladder39.08
- Vagina39.03
- Fallopian Tube37.95
- Muscle - Skeletal37.02
- Esophagus - Mucosa36.16
- Thyroid35.88
- Artery - Tibial35.74
- Nerve - Tibial34.17
- Artery - Aorta33.19
- Brain - Cerebellum32.04
- Artery - Coronary31.95
- Colon - Sigmoid31.5
- Adrenal Gland31.49
- Lung31.09
- Prostate30.87
And 29 more, listed on the interactive page.
- GO:0006302
- GO:0006457
- GO:0006974
- GO:0007165
- GO:0008284
- GO:0017148
- GO:0018105
- GO:0030177
- GO:0030307
- GO:0032435
- GO:0045732
- GO:0050821
- GO:0075342
- GO:1901797
- GO:1905337
- GO:1905818
- GO:2000042
- GO:2001234
- GO:0005634
- GO:0005654
- GO:0005829
- GO:0005886
- GO:0005956
- GO:0016605
- GO:0031519
- GO:0070822
- GO:0004674
- GO:0005515
- GO:0016301
- GO:0042802
- GO:0051879
- GO:0106310
regulation of catalytic activity
Studies
- biochemical: NVS_ENZ_hCK2a2b2, is one of one assay component(s) measured or calculated from the NVS_ENZ_hCK2a2b2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (163)
- A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years
- A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)
- A Drug Interaction Study of Cilnidipine and Valsartan
- A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
- A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets
- A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study
- A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People
- A Sourcing Study to Collect Human Blood Samples From Healthy Adults
- A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood
- A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
- A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain
- A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
- A Study of Silmitasertib (CX-4945) in Healthy Subject
- A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever
- A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
- Adherence With Iron Sprinkles Among High-Risk Infants
- Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids
- An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate
Drugs (1)
- Silmitasertib Casein kinase II alpha inhibitor